Neuphoria Therapeutics Announces CEO Transition and Consulting Role

Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialNeuphoria Therapeutics ( (NEUP) ) has issued an update. Neuphoria Therapeutics Inc. announced that Spyridon “Spyros” Papapetropoulos, M.D., who was appointed president and CEO under an employment agreement effective January 5, 2023, will step down as full-time president and CEO effective December 31, 2025, while remaining on the company’s board of directors. Under his employment agreement, he will receive severance equal to his annual base salary, target bonus and medical insurance premiums, paid partly in 2025 and the remainder in installments through 2026, and his participation in most employee benefit programs will end immediately, though his existing stock options will continue to vest and be exercisable under the company’s equity plan. Concurrently, Papapetropoulos has entered into a consulting agreement effective January 1, 2026, under which he will serve as interim CEO for up to twelve months at an hourly consulting rate, limited to roughly 40 hours per month, to support a planned strategic transaction and oversee leadership transition, with the arrangement set to terminate earlier if the company completes a strategic merger, change of control or similar deal. The most recent analyst rating on (NEUP) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Neuphoria Therapeutics stock, see the NEUP Stock Forecast page. Spark’s Take on NEUP Stock According to Spark, TipRanks’ AI Analyst, NEUP is a Neutral. The score is driven primarily by improved FY2025 financial trajectory (revenue step-up, positive free cash flow, and low leverage), partially offset by ongoing losses and volatility. Technicals are weak with the stock below major moving averages and negative MACD, and corporate events are pressured by the Phase 3 trial failure and program discontinuation; valuation remains constrained by negative earnings and no dividend yield data. To see Spark’s full report on NEUP stock, click here. More about Neuphoria Therapeutics Neuphoria Therapeutics Inc., formerly Bionomics Ltd., operates in the biopharmaceutical sector, focusing on developing therapeutics and related clinical programs, with governance overseen by a board of directors that includes its former chief executive as a continuing member. Average Trading Volume: 1,592,902 Technical Sentiment Signal: Sell Current Market Cap: $21.4M